Literature DB >> 18633605

Acute renal failure due to bilateral ureteral stone impaction in an HIV-positive patient.

Yoji Moriyama1, Yuzuru Minamidate, Mitsuru Yasuda, Hidetoshi Ehara, Mina Kikuchi, Tomohiro Tsuchiya, Takashi Deguchi, Hisashi Tsurumi.   

Abstract

A 51-year-old HIV-positive man treated with atazanavir for 9 months presented with anuria following right flank pain. Laboratory examination indicated renal insufficiency, and abdominopelvic computed tomography scanning showed bilateral hydroureteronephrosis, but no stones were visualized. Endoscopic procedures were performed to investigate the causes of ureteral obstruction and, if possible, to insert Double-J stents in the ureters. A yellowish stone composed of pure atazanavir was found at the right ureteral orifice, and retrograde pyelography revealed a filling defect in the left ureter found to be caused by an atazanavir stone. The patient's renal function recovered after removal of these stones.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18633605     DOI: 10.1007/s00240-008-0147-3

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  8 in total

1.  Atazanavir urinary stones in an HIV-infected patient.

Authors:  Jérôme Pacanowski; Jean-Marie Poirier; Isabelle Petit; Jean-Luc Meynard; Pierre-Marie Girard
Journal:  AIDS       Date:  2006-10-24       Impact factor: 4.177

2.  Atazanavir urolithiasis.

Authors:  Hernan R Chang; Pablo M Pella
Journal:  N Engl J Med       Date:  2006-11-16       Impact factor: 91.245

3.  Atazanavir-containing renal calculi in an HIV-infected patient.

Authors:  Peter L Anderson; Kenneth A Lichtenstein; Nel E Gerig; Jennifer J Kiser; Lane R Bushman
Journal:  AIDS       Date:  2007-05-11       Impact factor: 4.177

4.  Acute interstitial nephritis associated with atazanavir, a new protease inhibitor.

Authors:  Ursula C Brewster; Mark A Perazella
Journal:  Am J Kidney Dis       Date:  2004-11       Impact factor: 8.860

5.  Protease inhibitor-induced urolithiasis.

Authors:  D L Gentle; M L Stoller; T W Jarrett; J F Ward; K S Geib; A F Wood
Journal:  Urology       Date:  1997-10       Impact factor: 2.649

6.  Nonopaque crystal deposition causing ureteric obstruction in patients with HIV undergoing indinavir therapy.

Authors:  S P Blake; M M McNicholas; V Raptopoulos
Journal:  AJR Am J Roentgenol       Date:  1998-09       Impact factor: 3.959

7.  Urolithiasis in HIV-positive patients treated with atazanavir.

Authors:  Carine Couzigou; Michel Daudon; Jean Luc Meynard; Françoise Borsa-Lebas; Denise Higueret; Lélia Escaut; David Zucman; Jean-Yves Liotier; Jean-Louis Quencez; Karine Asselah; Thierry May; Didier Neau; Daniel Vittecoq
Journal:  Clin Infect Dis       Date:  2007-09-12       Impact factor: 9.079

8.  Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's Adverse Event Reporting System.

Authors:  Kirk M Chan-Tack; Melissa M Truffa; Kimberly A Struble; Debra B Birnkrant
Journal:  AIDS       Date:  2007-05-31       Impact factor: 4.177

  8 in total
  4 in total

Review 1.  Drug-Induced Kidney Stones and Crystalline Nephropathy: Pathophysiology, Prevention and Treatment.

Authors:  Michel Daudon; Vincent Frochot; Dominique Bazin; Paul Jungers
Journal:  Drugs       Date:  2018-02       Impact factor: 9.546

Review 2.  Atazanavir: its role in HIV treatment.

Authors:  Robin Wood
Journal:  Expert Rev Anti Infect Ther       Date:  2008-12       Impact factor: 5.091

3.  Clinical features and risk factors for atazanavir (ATV)-associated urolithiasis: a case-control study.

Authors:  Matthieu Lafaurie; Barbara De Sousa; Diane Ponscarme; Nathanael Lapidus; Michel Daudon; Laurence Weiss; Christophe Rioux; Erwan Fourn; Christine Katlama; Jean-Michel Molina
Journal:  PLoS One       Date:  2014-11-19       Impact factor: 3.240

4.  Is ritonavir-boosted atazanavir a risk for cholelithiasis compared to other protease inhibitors?

Authors:  Yohei Hamada; Takeshi Nishijima; Hirokazu Komatsu; Katsuji Teruya; Hiroyuki Gatanaga; Yoshimi Kikuchi; Shinichi Oka
Journal:  PLoS One       Date:  2013-07-16       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.